Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer

Future Oncology 2026 Open access

Read full text
Authors: Neal D Shore, Nasreen Khan, Rana R McKay, Niculae Constantinovici, Guifang Chen, Vlasta Hlebec, Shankar Srinivasan, Zdravko Vassilev, Daniel E Spratt
DOI: 10.1080/14796694.2026.2661772
Cited by: 1
References: 24

Abstract

Aims We assessed the proportion of patients with biochemical recurrence (BCR), the occurrence of BCR in risk groups according to prostate-specific antigen doubling time (PSA-DT), and clinical outcomes in risk groups.Patients and methods Retrospective observational study of patients with non-metastatic prostate cancer (PC) (n = 26,755) in the US using the Optum® PC electronic medical record database. Primary outcomes were the proportion of patients with BCR in prior radical prostatectomy (RP) or radiation therapy (RT) cohorts. Secondary outcomes included association between baseline characteristics and time to BCR, BCR risk group (high-risk: PSA-DT

Fields of Study & Subjects

Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Inflammatory Biomarkers in Disease Prognosis

Publication details

Journal / source
Future Oncology
Publisher
Informa UK Limited
Volume
22
Issue
11
Pages
1311–1319
Publication date
29 April 2026
Language
EN